Christopher Haqq - Feb 1, 2024 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Role: Title: Executive Vice President, Head of R&D and Chief Medical Officer
Signature: /s/Christopher Haqq
Stock symbol: ELTX
Transactions as of: Feb 1, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/5/2024, 06:01 AM
Previous filing: Jun 12, 2023
Next filing: Oct 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELTX	Stock Option (right to buy)	Award	$0	+28.2K		$0.00	28.2K	Feb 1, 2024	Common Stock	28.2K	$4.50	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty five percent (25%) of the stock options vest on February 1, 2025, the one-year anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Remarks:

Title: Executive Vice President, Head of R&D and Chief Medical Officer